96 related articles for article (PubMed ID: 4633407)
1. Immunologic evaluation of the cancer patient during immunotherapy.
Boehm OR; Boehm BJ; Jewell WR; Humphrey LJ
Natl Cancer Inst Monogr; 1972 Dec; 35():403-8. PubMed ID: 4633407
[No Abstract] [Full Text] [Related]
2. [The characterization of tumour-associated membrane-bound antigens and their implementation in the treatment of malignant melanoma (author's transl)].
Kokoschka EM
Wien Klin Wochenschr Suppl; 1979; 97():3-32. PubMed ID: 106559
[No Abstract] [Full Text] [Related]
3. Immunotherapy in patients with melanoma.
Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
[No Abstract] [Full Text] [Related]
4. Immunological studies on malignant melanomas of man.
Romsdahl MM; Cox IS
Yale J Biol Med; 1973 Dec; 46(5):693-701. PubMed ID: 4205125
[No Abstract] [Full Text] [Related]
5. [Immunology of malignant melanoma].
Misgeld V
Hautarzt; 1973 Dec; 24(12):511-9. PubMed ID: 4599321
[No Abstract] [Full Text] [Related]
6. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
[No Abstract] [Full Text] [Related]
7. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
8. Immunologic response of cancer patients modified by immunization with tumor vaccine.
Humphrey LJ; Boehm B; Jewell WR; Boehm OR
Ann Surg; 1972 Oct; 176(4):554-8. PubMed ID: 4627787
[No Abstract] [Full Text] [Related]
9. [Basis for a specific-active immunotherapy in malignant melanoma].
Mutzner PA; Stuhlmiller GM; Seigler HF; Stumpf WE; Sar M
Schweiz Med Wochenschr; 1981 Sep; 111(36):1322-5. PubMed ID: 7302537
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy for melanoma].
Kiniwa Y
Gan To Kagaku Ryoho; 2010 Apr; 37(4):629-33. PubMed ID: 20461891
[No Abstract] [Full Text] [Related]
11. Current immunotherapeutic strategies in malignant melanoma.
Agostino NM; Ali A; Nair SG; Mosca PJ
Surg Oncol Clin N Am; 2007 Oct; 16(4):945-73, xi. PubMed ID: 18022553
[TBL] [Abstract][Full Text] [Related]
12. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
13. In vivo delayed hypersensitivity reactions to partially purified human melanoma antigens.
Sutherland CM; Leong SP; Cooperband SR; Deckers PJ; Hornung MO; Krementz ET
J Surg Oncol; 1982 Aug; 20(4):221-6. PubMed ID: 7109625
[TBL] [Abstract][Full Text] [Related]
14. Delayed hypersensitivity reaction at metastatic tumor sites.
Gerner RE; Moore GE; Tabron DS
Rocky Mt Med J; 1975 Jan; 72(1):17-20. PubMed ID: 1053840
[No Abstract] [Full Text] [Related]
15. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H
Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158
[TBL] [Abstract][Full Text] [Related]
16. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
17. Adoptive transfer and specific active immunization of patients with malignant melanoma.
Seigler H; Buckley CE; Sheppard LB; Horne BJ; Shingleton WW
Ann N Y Acad Sci; 1976; 277(00):522-32. PubMed ID: 1069561
[No Abstract] [Full Text] [Related]
18. STUDIES ON IMMUNE RESPONSES OF RABBITS TO RABBIT SUBMAXILLARY ANTIGENS.
BEUTNER EH; GENCO R; DJANIAN AY; WITEBSKY E
Proc Soc Exp Biol Med; 1965 Apr; 118():893-8. PubMed ID: 14277705
[No Abstract] [Full Text] [Related]
19. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy for melanoma: how can tolerance be overcome?].
Robert C
Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
[No Abstract] [Full Text] [Related]
[Next] [New Search]
